<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02675829</url>
  </required_header>
  <id_info>
    <org_study_id>15-335</org_study_id>
    <nct_id>NCT02675829</nct_id>
  </id_info>
  <brief_title>Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers</brief_title>
  <official_title>A Phase 2 Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out what effects, a drug called ado-trastuzumab&#xD;
      emtansine has on the patient and their cancer which is thought to be controlled by the&#xD;
      abnormal HER2 gene.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>best overall response (ORR)</measure>
    <time_frame>2 years</time_frame>
    <description>As soon as evaluations for each tumor assessment are completed, the Investigator should assess the patient's overall response (target plus non- target lesions) based on criteria and overall response algorithms as defined in RECIST version 1.1. Scans must be assessable for all evaluations.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Solid Tumor Cancers</condition>
  <condition>Lung Cancer</condition>
  <condition>Bladder Cancer</condition>
  <condition>Urinary Tract Cancers</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Lung cancers, HER2 mutant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Lung cancers, HER2 amplified</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Colorectal cancers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Endometrial cancers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: Salivary gland cancers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6: Other solid cancers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ado-trastuzumab emtansine</intervention_name>
    <description>Ado-trastuzumab emtansine is administered intravenously at 3.6 mg/kg every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.</description>
    <arm_group_label>Cohort 1: Lung cancers, HER2 mutant</arm_group_label>
    <arm_group_label>Cohort 2: Lung cancers, HER2 amplified</arm_group_label>
    <arm_group_label>Cohort 3: Colorectal cancers</arm_group_label>
    <arm_group_label>Cohort 4: Endometrial cancers</arm_group_label>
    <arm_group_label>Cohort 5: Salivary gland cancers</arm_group_label>
    <arm_group_label>Cohort 6: Other solid cancers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults who are ≥18 years old.&#xD;
&#xD;
          -  Pathologically confirmed advanced solid tumor cancers&#xD;
&#xD;
          -  For Cohort 1, documented activating HER2 mutation in lung cancer by CLIA laboratory,&#xD;
             specifically exon 20 insYVMA (Y772_A775dup), insGSP (G778_P780dup), insTGT&#xD;
             (G776delinsVC), single base pair substitutions L755A, L755S, V777L, V659E, S310F, or&#xD;
             another HER2 mutation approved by the Principal Investigator&#xD;
&#xD;
          -  For Cohorts 2, 3, 4, 5, 6 documented HER2 amplification identified through next&#xD;
             generation sequencing by MSK-IMPACT or at another Clinical Laboratory Improvement&#xD;
             Amendments (CLIA) laboratory, or documented HER2 amplification by in-situ&#xD;
             hybridization (ISH) with HER2/CEP17 ratio ≥2.0 at a CLIA laboratory. Patients with&#xD;
             HER2 amplification identified by another method or criteria must be approved by the&#xD;
             Principal Investigator and may enroll in the &quot;Other&quot; Cohort 4.&#xD;
&#xD;
          -  Measurable or evaluable indicator lesion(s) as defined by RECIST v1.1. Patients&#xD;
             without RECIST measurable disease will be eligible for enrollment to &quot;Other&quot; cohort&#xD;
             provided their disease can be evaluated using another accepted response criteria (e.g.&#xD;
             Gynecologic Cancer InterGroup (GCIG) CA125 Response Criteria, modified PET Response&#xD;
             Criteria in Solid Tumors (PERCIST)). Patients with salivary gland cancers (Cohort 5)&#xD;
             may be eligible on the basis of evaluable disease on modified PET.&#xD;
&#xD;
          -  Karnofsky Performance Status 70% or above.&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) ≥50% measured by echocardiogram (ECHO) or&#xD;
             multiple gated acquisition scan (MUGA).&#xD;
&#xD;
          -  Negative β-human chorionic gonadotropin (hCG) pregnancy test within 2 weeks before&#xD;
             enrollment for premenopausal women of reproductive capacity and for women less than 12&#xD;
             months after menopause. Pregnancy screening will be conducted for women up to the age&#xD;
             of 50 years per institutional standard.&#xD;
&#xD;
          -  Women of childbearing potential must agree to use of a highly effective method of&#xD;
             contraception. Effective contraception is required during treatment and for 7 months&#xD;
             following the last dose for female participants of reproductive potential and during&#xD;
             treatment and for 4 months following the last dose for male participants with female&#xD;
             sexual partners of reproductive potential. Male participants should also refrain from&#xD;
             donating sperm during treatment and for 4 months following the last dose.&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/µL within 30 days prior to C1D1&#xD;
&#xD;
          -  Platelet count ≥ 100,000/µL within 30 days prior to C1D1&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN), in case of&#xD;
             Gilbert's syndrome, ≤ 2x ULN within 30 days prior to C1D1&#xD;
&#xD;
          -  Aspartate aminotransferase and/or alanine aminotransferase ≤ 3 x ULN (≤ 5 x ULN if&#xD;
             liver metastases are present) within 30 days prior to C1D1&#xD;
&#xD;
          -  Provide written, informed consent to participate in the study and follow the study&#xD;
             procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior therapy resulting in cumulative epirubicin dose ≥ 900mg/m2 or cumulative&#xD;
             doxorubicin dose ≥ 500mg/m2 or equivalent dose of another anthracycline.&#xD;
&#xD;
          -  Prior therapy with ado-trastuzumab emtansine (patients who had prior trastuzumab or&#xD;
             other HER2 targeted agents are eligible).&#xD;
&#xD;
          -  Symptomatic congestive heart failure (New York Heart Association Classification&#xD;
             II-IV).&#xD;
&#xD;
          -  Myocardial infarction or unstable angina within 6 months of enrollment.&#xD;
&#xD;
          -  Unstable ventricular arrhythmia requiring treatment.&#xD;
&#xD;
          -  Grade 3 or worse peripheral neuropathy as defined by CTCAE v4.1.&#xD;
&#xD;
          -  Women who are pregnant or breast-feeding.&#xD;
&#xD;
          -  Known hypersensitivity to any component of ado-trastuzumab emtansine.&#xD;
&#xD;
          -  History of interstitial lung disease or pneumonitis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bob Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bob Li, MD</last_name>
    <phone>646-608-3791</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gopakumar Iyer, MD</last_name>
    <phone>646-422-4362</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities)</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bob Li, MD</last_name>
      <phone>646-608-3791</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth (Limited Protocol Activities)</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bob Li, MD</last_name>
      <phone>646-608-3791</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen (Limited Protocol Activities)</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bob Li, MD</last_name>
      <phone>646-608-3791</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities)</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bob Li, MD</last_name>
      <phone>646-608-3791</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester (Limited Protocol Activities)</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bob Li, MD</last_name>
      <phone>646-608-3791</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bob Li, MD</last_name>
      <phone>646-608-3791</phone>
    </contact>
    <contact_backup>
      <last_name>Gopakumar Iyer, MD</last_name>
      <phone>646-422-4362</phone>
    </contact_backup>
    <investigator>
      <last_name>Bob Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau (Limited Protocol Activities)</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bob Li, MD</last_name>
      <phone>646-608-3791</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 3, 2016</study_first_submitted>
  <study_first_submitted_qc>February 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2016</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2 mutant</keyword>
  <keyword>HER2 amplified</keyword>
  <keyword>Ado-Trastuzumab Emtansine</keyword>
  <keyword>15-335</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Ado-Trastuzumab Emtansine</mesh_term>
    <mesh_term>Maytansine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

